I'm human

Forced degradation, synonymous with stress testing and purposeful degradation, serves as a valuable tool for predicting the stability of pharmaceutical substances or products. It enables the assessment of impurity profiles and behaviors under various stress conditions. In development, forced degradation plays a crucial role in designing formulations, setting specifications, and establishing analytical methods under the quality-by-design (QbD) paradigm. The specific nature of stress testing varies depending on the individual drug substance and product type. Manufacturing process, product handling, and storage can be optimized through understanding of degradation mechanisms. To minimize deficiencies in ANDA submissions, this article provides general recommendations for conducting forced degradation studies and utilizing knowledge gained to develop stability-indicating analytical methods. Stress conditions include heat, hydrolytic, oxidative, and photolytic degradation, which can be controlled by selecting suitable reagents and varying conditions. A generic approach for stress testing has been proposed, with generally recommended degradation levels between 5-20%. Photostability testing is crucial for photo-labile compounds, involving exposure to a minimum of 1.2 million lux hours and 200 watt hours per square meter light. Samples should be analyzed for changes in physical properties and assay/degradants. The ICH Q1B decision tree can guide product labeling decisions, ensuring concordance with the reference listed drug (RLD) and USP monograph recommendations. Drug Stability Testing: A Comprehensive Approach To ensure the quality and efficacy of drug products, it is essential to conduct stability testing under various environmental conditions. This includes exposing substances and drug products to dry and wet heat, as well as liquid drug products exposed only to dry heat. Temperature studies should be conducted in increments of 10°C above routine accelerated testing levels, while maintaining a relative humidity of 75% or higher. Testing at multiple time points can provide valuable insights into the rate of degradation and primary and secondary degradation products. If stress conditions result in minimal degradation, it is crucial to apply sufficient stress beyond that achieved by accelerated conditions (40°C for 6 months) before terminating the study. Acid and base hydrolysis testing can be carried out on drug substances and products in solution at ambient temperature or elevated temperatures. The selection of acid or base type and concentration depends on the stability of the drug substance, with suitable reagents including hydrochloric or sulfuric acid for acid hydrolysis and sodium or potassium hydroxide for base hydrolysis. For lipophilic drugs, inert co-solvents may be used to solubilize the drug substance. It is essential to consider the functional groups present in the drug molecule when selecting a co-solvent. Prior knowledge of a compound can be beneficial in selecting stress conditions. For instance, if a compound contains ester functionality and is labile to base hydrolysis, low concentrations of a base may be used. Oxidative degradation testing can be complex, with hydrogen peroxide being the primary oxidizing agent due to its mimicry of possible peroxides in excipients. Other oxidizing agents, such as metal ions, oxygen, and radical initiators, can also be used depending on the drug substance. Solutions of drug substances and solid/liquid products can be subjected to oxidative degradation at various concentrations and conditions. Analyzing samples at different time intervals can provide valuable information on the progress of degradation and help distinguish primary degradants from secondary degradants. The selection of analysis methods for a stability-indicating assay heavily depends on the drug molecule's functional groups and stress conditions. The preferred method for this type of analysis is reverse-phase high-performance liquid chromatography (HPLC) due to its compatibility with aqueous and organic solutions, precision, sensitivity, and ability to detect polar compounds. To achieve accurate results, it's essential to carefully select column types, temperatures, and mobile phase pH levels. The separation of peaks should also be optimized by considering the use of gradient elution methods that can capture early-eluting highly polar compounds and highly retained nonpolar compounds. When analyzing stressed samples, it's crucial to mimic sample preparation as closely as possible and assess potential elution patterns using gradient methods. Neutralization or dilution may be necessary for acid- and base-hydrolyzed samples. Chromatographic profiles of stressed samples should be compared with those of relevant blanks and unstressed samples to determine the origin of peaks, excluding blank peaks from calculations. The amount of impurities obtained under each stress condition should be reported along with chromatograms showing all peaks. For chiral drugs, analysis with chiral methods is necessary to establish stereochemical purity and stability. The analytical method chosen should detect impurities at low levels (0.05% or lower) and have peak responses within the detector's linearity range. Degradation product identification and characterization are essential based on formal stability results in accordance with ICH requirements. Conventional methods or hyphenated techniques can be used for this purpose, providing better insight into impurity structures that may aid in controlling such impurities with tighter limits. Studies reveal that qualification thresholds are exceeded in many instances, necessitating advanced detection methods like UV and mass spectroscopy to analyze stressed samples. A detector capable of capturing 3D data is essential to detect spectral non-homogeneity. Diode array detectors offer the advantage of examining peak profiles across multiple wavelengths, but limitations arise when noise levels are high or co-eluting impurities/degradants have similar UV profiles. In such cases, chromatographic parameters must be modified to achieve necessary separation. Optimal wavelength selection is crucial for detecting all potential impurities/degradants. If overlap exists between analyte and impurity/degradant peaks, multiple wavelengths may be required. Overlaying separation signals at different wavelengths can help identify dissimilarities in peak profiles. Peak purity analysis is essential in stability indicating method development, utilizing spectral information from diode array detectors to establish the uniqueness of a compound. Software parameters must be set according to manufacturer guidelines, considering peak height requirements and threshold values for detecting co-eluting peaks. However, peak purity does not guarantee absolute purity, as limitations arise when co-eluting peaks are similar or below detection limits. Mass balance evaluation is another crucial aspect, assessing the adequacy of a stability indicating method by adding assay values and impurity/degradant amounts to achieve 100% of the initial value (unstressed assay value) while considering analytical error margins. Stress testing should be conducted to examine analyte and impurity peaks under various conditions. This includes studying differences in UV absorption due to external standards, as well as exploring potential losses of volatile impurities, formation of non-UV absorbing compounds, and retention of compounds in the column. Alternative detection techniques like RI LC/MS can be employed to account for non-UV absorbing degradants. Termination of study Stress testing may terminate once adequate exposure to stress conditions is ensured. The typical activation energy of drug substance molecules ranges from 12–24 kcal/mol (18). A compound may not degrade under every single stress condition, and general guidelines on exposure limits are cited in a review article (10). Other considerations Stress testing may not be necessary for drug substances and products with pharmacopeial methods, used within USP limitations. When a generic drug product uses a different polymorphic form from the RLD, stress testing is required to evaluate physiochemical changes of the polymorphic form. Forced degradation in QbD paradigm A well-designed, forced degradation study is essential for analytical method development in a QbD paradigm. It helps establish specificity and predict potential degradation products that could form during formal stability studies. This knowledge can also provide useful information regarding excipient selection and formulation development. Incorporating all potential impurities into the analytical method and establishing peak purity helps avoid unnecessary method re-development and revalidation. Understanding chemical behavior under various stress conditions provides valuable information for selecting excipients, examining drug-excipient or drug-drug interactions in combination products, and developing more stable formulations. For the formulation of drug products, consideration should be given to oxidation, where addition of an antioxidant may be necessary. If a drug substance is labile to acid or undergoes stereochemical conversion in acidic medium, delayed-release formulations may be required. Acid/base hydrolysis testing can provide valuable insights into the formulation of liquid or suspension-based drug products. Understanding gained from forced degradation studies can facilitate improvements in manufacturing processes. If photostability testing indicates that a drug substance is photolabile, caution should be taken during manufacturing to prevent degradation. Thermal stress testing of drug substances and products can provide information on process development, such as wet versus dry processing and temperature selection. Additionally, understanding degradation mechanisms and products can help identify factors contributing to stability failures, including ambient temperature, humidity, and light. This knowledge can inform the selection of packaging materials that protect against these factors. The design of stress studies is crucial for Quality by Design (QbD) approaches in the pharmaceutical industry, providing insights into formulation selection prior to intensive development studies. A thorough understanding of degradation mechanisms is essential for QbD approaches in analytical method development and setting acceptance criteria for shelf-life monitoring. Stress testing can provide valuable insights into physical form, stereochemical stability, packaging, and storage conditions. For generic drugs, stress testing is particularly important due to the potential for qualitative and quantitative differences in formulation compared to the reference listed drug (RLD). 1. Srinivasan A, Iser R, Gill D. Analytical procedures for pharmaceuticals. Pharm Technol 35(2):58–67 (2011). 2. Klick S, et al. Chemical stability of pharmaceuticals. Pharm Technol 29(2):48–66 (2005). 3. Alsante KM, Martin L, Baertschi SW. Forced degradation studies for pharmaceuticals. Pharm Technol 27(2):60-72 (2003). 4. Reynolds DW, et al. Analytical procedures for pharmaceuticals. Pharm Technol 26(2):48–56 (2002). 5. Alsante KM, et al. Stability of pharmaceuticals. Advanced Drug Delivery Reviews 59:29–37 (2007). 6. FDA. Guidance on analytical procedures and methods validation chemistry, manufacturing, and controls documentation. Draft document. Rockville, MD; August 2000. 7. ICH. Specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances. Geneva; October 1999. 8. ICH. Impurities in new drug substances. Geneva; October 2006. 9. FDA. Impurities in drug substances. Draft document. Rockville, MD; August 2005. 10. FDA. Impurities in drug products. Draft document. Rockville, MD; November 2010. 11. EMA. Guideline on the limits of genotoxic impurities. Committee for Medical Products for Human Use (CHMP). Geneva; January 1, 2007. 12. Conners KA, et al. Chemical stability of pharmaceuticals. New York: Wiley and Sons; 1986.